Kevin Sayer serves as Executive Chairman of Dexcom, Inc., a pioneering company in continuous glucose monitoring (CGM) technology that empowers people with diabetes to manage their health more effectively. With nearly three decades of experience in the medical device industry, Sayer joined Dexcom in 2005 as Vice President of Operations. Prior to that, he held senior leadership positions at ATS Medical, Inc., and Nova Biomedical Corporation, where he developed expertise in manufacturing, quality systems, and scaling innovative medical technologies from concept to market. Sayer's career at Dexcom has been defined by rapid advancement and transformative achievements. He progressed to Chief Operating Officer in 2007, President in 2011, and Chief Executive Officer in 2015, leading the company through explosive growth. Under his stewardship, Dexcom launched groundbreaking products like the Dexcom G6 and G7 CGM systems, achieved multiple FDA approvals, expanded globally, and secured strategic partnerships, including integrations with insulin pumps. These efforts propelled Dexcom's revenue from under $100 million to over $3 billion annually, establishing it as a leader in diabetes care innovation. As Executive Chairman since 2022, following the appointment of a new CEO, Sayer chairs the Board of Directors, providing strategic oversight and guidance to sustain Dexcom's momentum. His visionary leadership has not only driven commercial success but also advanced the company's mission to improve lives through accessible, real-time glucose data, earning him recognition as a key architect of Dexcom's rise in the digital health landscape.